February 14, 2025 — Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to NovoLog (insulin aspart) for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus…Original Article
FDA Approves Merilog (insulin-aspart-szjj), a Biosimilar to NovoLog
